<DOC>
	<DOCNO>NCT01456182</DOCNO>
	<brief_summary>This trial ass tolerability safety AFX-2 range five dose level adult low- , intermediate- high-risk Chronic Lymphocytic Leukemia ( CLL ) . The trial also determine impact dose quality life index biological immune response , assess maximum tolerate dose and/or dose-limiting toxicity study population .</brief_summary>
	<brief_title>Phase 1B- Open Label Dose-Ranging Study Oral AFX-2 Adults With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>1 . Adult men woman &gt; 18 year age 2 . Diagnosis CLL per NCI Working Group Criteria ; phenotypic evidence ( i.e.. flow cytometry bone marrow biopsy ) chronic lymphocytic leukemia ( MEDDRA Code 10008960 ; ICDO39823 ) 3 . Disease meet criterion lowrisk ( Rai Stage 0 ) , intermediaterisk ( Rai Stage I II ) , highrisk ( Rai Stage IIIIV ) disease 4 . Life expectancy ≥ 3 month Screening . 5 . ECOG performance status 03 6 . Laboratory parameter ( take &lt; 14 day Study Day 0 ) : Hematologic parameter : Hemoglobin &gt; 9 gm/dL ( stable , drop ) ; Absolute Granulocyte Count ( AGC ) &gt; 1.0 x 109/L ; Platelets &gt; 50 x 109/L ; require immediate transfusion . Coagulation : PT/PTT/INR : ± 10 % NL lab ; INR : 1.01.43 BUN &lt; 40 ; serum Creatinine ≤ 2.0 mg/dL , OR Creatinine Clearance &gt; 90 mL/min/1.73m2 IF serum Creatinine &gt; 2.0 mg/dL Liver function test ( AST , ALT , ALP , LDH ) : &lt; 2.5 x institutional ULN ; Total bilirubin : &lt; 2.0 x institutional ULN Human Immunodeficiency Virus ( HIV ) negative Pregnancy test : negative urine pregnancy test female childbearing potential , 7 . Free disease prior malignancy/ies &gt; 2 year , except basal cell squamous cell carcinoma skin , carcinoma situ cervix breast . 8 . If surgically sterile , postmenopausal ( &gt; 12 month menstrual flow ) , willing practice birth control ( barrier + contraception ) throughout duration study . 9 . Able willing swallow capsule . 10 . Willing limit alcohol intake study treatment period . 11 . Willing sign inform consent . 1 . Lymphoproliferative disease CLL 2 . Prior use test article ( AFX2 ) , ginsengcontaining product ( American , Asian , etc . ) ≤ 1 year prior study entry . 3 . Known allergy test article ginsengcontaining product 4 . Active infection require systemic treatment 5 . Prior current therapy : Splenectomy . Currently require anticoagulant therapy Requiring active treatment BCLL ≤ 28 day posttreatment BCLL condition requiring : chemotherapy , radiation therapy , monoclonal antibody , systemic steroid , antihistamine nonsteroidal antiinflammatory drug , include ibuprofen , indomethacin , COX2 inhibitor etc . ≤ 10 day : nonsteroidal hormonal therapy ( contraception thyroid ) ≤ 10 day : antibiotic prophylaxis History therapy immunological reagent , allogeneic bone marrow transplant , monoclonal antibody therapy , intravenous immunoglobulin , hematopoietic stem cell transplantation . ( Note : Immunotherapy allergy permit long last treatment ( ) prior CLL diagnosis ( b ) &gt; 5 year prior trial enrollment . ) &lt; 90 day post treatment chlorambucil &lt; 90 day post general anesthesia 6 . Uncontrolled intercurrent condition , include , limited , cardiovascular , pulmonary , renal , hepatic , GI , GU , neurologic , metabolic , psychiatric , etc . 7 . Current prior investigational product procedure &lt; 56 day precede study entry ( Baseline Visit 2 ; Study Day 0 ) . 8 . Unwilling discontinue use nonprescription ( OTC ) , nutritional dietary supplement study period ( define protocol ) . 9 . Pregnant , lactate . 10 . Any condition , personal social situation preclude limit ability participant provide inform consent comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>